CStone Pharmaceuticals - ESG Rating & Company Profile powered by AI
The Disclosure score includes seventeen United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Industry, Innovation & Infrastructure' and 'Life on Land'. The webpage contains a Q&A section on CStone Pharmaceuticals. Comprehensive ESG assessment of CStone Pharmaceuticals are reached by registering for free.
CStone Pharmaceuticals in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.0; made up of an environmental score of 4.0, social score of 5.7 and governance score of 5.3.
5.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 724 | Skye Bioscience Inc | 5.1 | High |
| 724 | Xbrane Biopharma AB | 5.1 | High |
| 744 | CStone Pharmaceuticals | 5.0 | High |
| 744 | CSL Ltd | 5.0 | High |
| 744 | CASI Pharmaceuticals Inc | 5.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does CStone Pharmaceuticals have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose current and historical energy intensity?
Sign up for free to unlockDoes CStone Pharmaceuticals report the average age of the workforce?
Sign up for free to unlockDoes CStone Pharmaceuticals reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose its ethnicity pay gap?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose cybersecurity risks?
Sign up for free to unlockDoes CStone Pharmaceuticals offer flexible work?
Sign up for free to unlockDoes CStone Pharmaceuticals have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose the number of employees in R&D functions?
Sign up for free to unlockDoes CStone Pharmaceuticals conduct supply chain audits?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes CStone Pharmaceuticals conduct 360 degree staff reviews?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose the individual responsible for D&I?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose water use targets?
Sign up for free to unlockDoes CStone Pharmaceuticals have careers partnerships with academic institutions?
Sign up for free to unlockDid CStone Pharmaceuticals have a product recall in the last two years?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose incidents of discrimination?
Sign up for free to unlockDoes CStone Pharmaceuticals allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas CStone Pharmaceuticals issued a profit warning in the past 24 months?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose parental leave metrics?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose the pay ratio of women to men?
Sign up for free to unlockDoes CStone Pharmaceuticals support suppliers with sustainability related research and development?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes CStone Pharmaceuticals reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs CStone Pharmaceuticals involved in embryonic stem cell research?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose its waste policy?
Sign up for free to unlockDoes CStone Pharmaceuticals report according to TCFD requirements?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose energy use targets?
Sign up for free to unlockDoes CStone Pharmaceuticals disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes CStone Pharmaceuticals have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for CStone Pharmaceuticals
These potential risks are based on the size, segment and geographies of the company.
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.